MedGenome

End-to-end multiomics testing capability across all major disease areas from South Asia's largest CAP-accredited facility.

Over 1,300 genetic tests spanning oncology, inherited disease, reproductive health, infectious disease and preventive wellness.

Diagnostic tests delivered at global quality standards but priced for accessibility across South Asia.

A proprietary, independent NGS lab and genetic-variant dataset built on India's unusually diverse population genetics.

Direct end-patients undergoing clinical genetic testing across oncology, reproductive health, inherited disease and infectious disease categories.

A pan-India network of partnered hospitals and referring clinicians that source samples for MedGenome's lab network.

Global pharma and biotech firms that use MedGenome's genomic research services and South Asian variant data for drug development.

Long-running B2B2C relationships with thousands of partnered hospitals and clinicians who route patient samples to MedGenome.

A self-serve personal genomics/wellness testing line sold directly to individual consumers, launched September 2021 per contemporaneous BioSpectrum India coverage (also corroborated by Atlas signal id 769); the company's own about-us page separately states 2022 without elaboration.

Genetic tests are ordered through a large network of partnered hospitals and referring clinicians across India.

MedGenome has acquired stakes in regional diagnostic chains (Trident, GenX, Green Cross, Medcare, Siddhi, Prognosis) to reach Tier 2/3 cities.

MedGenome's direct-to-consumer personal genomics division. Launched September 2021 per contemporaneous BioSpectrum India coverage (also corroborated by Atlas signal id 769); the company's own about-us page separately states 2022 without elaboration.

A US lab acquired from Lifecode Health extends MedGenome's genomic services directly to American biotech and pharma customers.

Core operations of running genetic tests and sequencing exomes/genomes at scale.

A steady cadence of majority-stake acquisitions of regional diagnostic chains to extend reach into Tier 2/3 India.

Research programs developing proprietary biomarker suites for cancer immunotherapy and other disease areas.

Cumulative exome and genome sequencing volume built up over more than a decade of operation.

A large in-house team of scientists, genome analysts and bioinformatics engineers.

MedGenome is a founding member of this nonprofit consortium sequencing 100,000 Asian genomes, committing capital and data-science capacity.

Sequencing-technology partner; MedGenome was first in South Asia to deploy Illumina's NovaSeq X Plus platform.

Life-sciences-focused investor and strategic partner across two funding rounds (2022 and 2025).

Fees from processing genetic tests ordered by hospitals, clinicians and patients.

Software and bioinformatics platform licensing sold alongside diagnostic services.

Global biopharma researchers pay to access MedGenome's genetic-variant database for drug discovery and target validation.

The cost of sequencing a whole human genome fell from over $10 million a decade earlier to approximately $1,000, per Chairman & Global CEO Sam Santhosh; MedGenome was the first company to bring this cost point to India and, at the time, the only Indian firm sequencing a full genome for under $1,000.

After deploying Illumina's NovaSeq X Plus sequencing platform, MedGenome said it anticipates bringing the reagent cost of human whole-genome sequencing down to $200.

MedGenome Labs Limited's total expenses were approximately ₹276.3 crore in FY25, down 17% year-on-year, against an estimated EBITDA of ₹81.0 crore, per Inc42's analysis of the company's financial filings.